Form 4: Dermata Therapeutics Executive Acquires Stock Options

Maria E. Bedoya-Toro, SVP of Regulatory Affairs at Dermata Therapeutics, acquired 8,000 stock options on January 13, 2025.

Summary

• Maria E. Bedoya-Toro, the SVP of Regulatory Affairs at Dermata Therapeutics, acquired 8,000 stock options on January 13, 2025.
• The exercise price of these options is $1.38 per share.
• The options vest 25% after 12 months from the grant date, with the remaining 75% vesting in 36 equal monthly installments starting after the first year.
• The options expire on January 12, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally neutral to positive. The vesting schedule suggests a long-term commitment from the executive.

Industry Context

This is a standard practice for companies to grant stock options to executives as part of their compensation packages, aligning their interests with the company's performance.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation across the biotechnology and pharmaceutical industries.
• Vesting schedules, such as the one described in this document, are typical to incentivize long-term commitment and performance.
• The specific terms of the options, such as the exercise price and vesting schedule, are often tailored to the individual executive and the company's overall compensation strategy.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• This type of compensation is common and generally expected by stakeholders.

Key Dates

Keywords

stock options, executive compensation, insider trading, Dermata Therapeutics, DRMA, regulatory affairs